TransVax is used for the prevention of reactivation of latent cytomegalovirus (CMV) or introduction of CMV through donor cells or tissues in transplant recipients.
The vaccine is formulated with a poloxamer designed to enhance primarily a cellular immune response.
TransVax has received orphan drug status for transplant patients.
Vical released encouraging results from a completed Phase 2 trial of the vaccine in patients undergoing hematopoietic stem cell transplants, in September 2010.
Currently, Vical is in talks with regulatory authorities to confirm the design of a planned Phase 3 trial, which is expected to begin in the second half of 2011.